{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:59:14Z","timestamp":1790096354579,"version":"4.0.1"},"reference-count":34,"publisher":"American Society for Microbiology","issue":"8","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["J Clin Microbiol"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:p>\n            Third-generation cephalosporin resistance among\n            <jats:named-content content-type=\"genus-species\">Enterobacteriaceae<\/jats:named-content>\n            , mediated by the spread of extended-spectrum \u03b2-lactamases (ESBLs), is a very serious medical concern with limited therapeutic options. Enmetazobactam (formerly AAI101) is a novel penicillanic sulfone \u03b2-lactamase inhibitor active against a wide range of ESBLs. The combination of enmetazobactam and cefepime has entered phase 3 development in patients with complicated urinary tract infections.\n          <\/jats:p>","DOI":"10.1128\/jcm.00607-19","type":"journal-article","created":{"date-parts":[[2019,6,4]],"date-time":"2019-06-04T16:18:46Z","timestamp":1559665126000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":17,"title":["Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel \u03b2-Lactamase Inhibitor Enmetazobactam"],"prefix":"10.1128","volume":"57","author":[{"given":"Adam","family":"Belley","sequence":"first","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley A.","family":"Fedler","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy A.","family":"Watters","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert K.","family":"Flamm","sequence":"additional","affiliation":[{"name":"JMI Laboratories, North Liberty, Iowa, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart","family":"Shapiro","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Knechtle","sequence":"additional","affiliation":[{"name":"Allecra Therapeutics SAS, Saint-Louis, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.14.4.933-951.2001"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/jtm\/taw102"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2016.04.022"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(18)30605-4"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(18)30278-X"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717295115"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01076-18"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix034"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12565"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-017-0334-x"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkt450"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153696"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2018.12163"},{"key":"e_1_3_3_17_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00105-19"},{"key":"e_1_3_3_18_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00514-19"},{"key":"e_1_3_3_19_2","volume-title":"Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically","author":"Clinical and Laboratory Standards Institute","year":"2015","unstructured":"Clinical and Laboratory Standards Institute. 2015. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u201410th ed. CLSI document M07-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"10"},{"key":"e_1_3_3_20_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial susceptibility testing; 28th informational supplement. CLSI M100-S28. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_21_2","volume-title":"Performance standards for antimicrobial disk susceptibility tests","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Performance standards for antimicrobial disk susceptibility tests; approved standard\u201413th ed. CLSI document M02-A10. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"13"},{"key":"e_1_3_3_22_2","volume-title":"Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101, abstr P0157","author":"Huband M","year":"2018","unstructured":"Huband M, Rhomberg PR, Fedler KA, Flamm RK, Knechtle P, Shapiro S. 2018. Disk content assessment and proposed breakpoint interpretive criteria for cefepime in combination with AAI101, abstr P0157. Abstr 28th European Congress of Clinical Microbiology and Infectious Diseases, Madrid, Spain, 21 to 24 April 2018."},{"key":"e_1_3_3_23_2","volume-title":"Cefepime-enmetazobactam (formerly AAI101; 30\/20 \u03bcg) and cefepime (30 \u03bcg) disk diffusion quality control ranges using a CLSI M23 (2018) multi-laboratory study design, abstr P2778","author":"Huband MD","year":"2019","unstructured":"Huband MD, Fedler KA, Watters AA, Belley A, Knechtle P, Flamm RK. 2019. Cefepime-enmetazobactam (formerly AAI101; 30\/20 \u03bcg) and cefepime (30 \u03bcg) disk diffusion quality control ranges using a CLSI M23 (2018) multi-laboratory study design, abstr P2778. Abstr 29th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands, 13 to 16 April 2019."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dki074"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.7.3110-3113.2005"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkv004"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00033-15"},{"key":"e_1_3_3_28_2","volume-title":"Development of in vitro susceptibility testing criteria and quality control parameters","author":"Clinical and Laboratory Standards Institute","year":"2018","unstructured":"Clinical and Laboratory Standards Institute. 2018. Development of in vitro susceptibility testing criteria and quality control parameters; approved standard\u20144th ed. CLSI document M23-04. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"4"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01457-06"},{"key":"e_1_3_3_30_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2017","unstructured":"Clinical and Laboratory Standards Institute. 2017. Performance standards for antimicrobial susceptibility testing; 27th informational supplement. CLSI M100-S27. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.14.1.67-72.1981"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.44.9.2382-2388.2000"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkx181"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.7860\/JCDR\/2015\/11029.5537"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1586\/14787210.6.6.805"},{"key":"e_1_3_3_36_2","volume-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute","year":"2019","unstructured":"Clinical and Laboratory Standards Institute. 2019. Performance standards for antimicrobial susceptibility testing. 29th informational supplement. CLSI M100-S29. Clinical and Laboratory Standards Institute, Wayne, PA."},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.00788-17"}],"container-title":["Journal of Clinical Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00607-19","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/JCM.00607-19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,3,5]],"date-time":"2022-03-05T10:32:44Z","timestamp":1646476364000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/JCM.00607-19"}},"subtitle":[],"editor":[{"given":"Robin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":34,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1128\/JCM.00607-19"],"URL":"https:\/\/doi.org\/10.1128\/jcm.00607-19","relation":{},"ISSN":["0095-1137","1098-660X"],"issn-type":[{"value":"0095-1137","type":"print"},{"value":"1098-660X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"2019-04-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-30","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-07-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e00607-19"}}